杜匹单抗对严重特应性皮炎的 2 型炎症合并症产生了良好的反应。

Q2 Medicine

Clinical and Molecular Allergy Pub Date : 2021-06-16 DOI:10.1186/s12948-021-00144-x

Eustachio Nettis, Lucia Masciopinto, Elisabetta Di Leo, Nicola De Candia, Marcello Albanesi, Danilo Di Bona, Nicola Quaranta, Luigi Macchia

{"title":"杜匹单抗对严重特应性皮炎的 2 型炎症合并症产生了良好的反应。","authors":"Eustachio Nettis, Lucia Masciopinto, Elisabetta Di Leo, Nicola De Candia, Marcello Albanesi, Danilo Di Bona, Nicola Quaranta, Luigi Macchia","doi":"10.1186/s12948-021-00144-x","DOIUrl":null,"url":null,"abstract":"Background: This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects.Case presentation: We report on effects of dupilumab in a patient with severe AD, a long-standing history of a mild, perennial allergic rhino-conjunctivitis, moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).Conclusions: Patients suffering from AD, asthma, allergic rhinitis and CRSwNP may be eligible for dupilumab single treatment that is possibly advantageous also from the pharmaco-economic standpoint.","PeriodicalId":38753,"journal":{"name":"Clinical and Molecular Allergy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207639/pdf/","citationCount":"0","resultStr":"{\"title\":\"Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis.\",\"authors\":\"Eustachio Nettis, Lucia Masciopinto, Elisabetta Di Leo, Nicola De Candia, Marcello Albanesi, Danilo Di Bona, Nicola Quaranta, Luigi Macchia\",\"doi\":\"10.1186/s12948-021-00144-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects.Case presentation: We report on effects of dupilumab in a patient with severe AD, a long-standing history of a mild, perennial allergic rhino-conjunctivitis, moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).Conclusions: Patients suffering from AD, asthma, allergic rhinitis and CRSwNP may be eligible for dupilumab single treatment that is possibly advantageous also from the pharmaco-economic standpoint.\",\"PeriodicalId\":38753,\"journal\":{\"name\":\"Clinical and Molecular Allergy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207639/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Molecular Allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s12948-021-00144-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Molecular Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12948-021-00144-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

背景：本病例是首次报道用杜比单抗快速、成功地治疗同一患者的重度特应性皮炎（AD）和合并的2型炎症性疾病，且无副作用：我们报告了双鲁单抗对一名患有严重特应性皮炎、长期轻度过敏性鼻结膜炎、中度哮喘和慢性鼻炎伴鼻息肉（CRSwNP）的患者的治疗效果：结论：患有自闭症、哮喘、过敏性鼻炎和慢性鼻炎伴鼻息肉（CRSwNP）的患者可能有资格接受杜必鲁单抗的单一治疗，从药物经济学的角度来看，这可能也是有利的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis.

查看原文本刊更多论文

Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis.

Background: This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects.

Case presentation: We report on effects of dupilumab in a patient with severe AD, a long-standing history of a mild, perennial allergic rhino-conjunctivitis, moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

Conclusions: Patients suffering from AD, asthma, allergic rhinitis and CRSwNP may be eligible for dupilumab single treatment that is possibly advantageous also from the pharmaco-economic standpoint.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical and Molecular Allergy Medicine-Immunology and Allergy

CiteScore

8.20

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Clinical and Molecular Allergy is an open access, peer-reviewed, online journal that publishes research on human allergic and immunodeficient disease (immune deficiency not related to HIV infection/AIDS). The scope of the journal encompasses all aspects of the clinical, genetic, molecular and inflammatory aspects of allergic-respiratory (Type 1 hypersensitivity) and non-AIDS immunodeficiency disorders. However, studies of allergic/hypersensitive aspects of HIV infection/AIDS or drug desensitization protocols in AIDS are acceptable. At the basic science level, this includes original work and reviews on the genetic and molecular mechanisms underlying the inflammatory response.